Incidence of Hypertension in Asthma Patients Who Treated With Beta-2 Agonists Bronchodilators

Abstract

Objective: To determine the prevalence of hypertension in hospitalized patients with asthma who were treated with beta-2 agonists. To evaluate the correlation between the duration of the use of beta-2 agonist with the incidence of hypertension.Methods: This research is a descriptive epidemiological, observational cross-sectional and retrospective study design. The study population was all adult asthma patients (age ≥ 25) without a concomitant diseases such as hypertension or metabolic syndrome treated with β2 agonists as a bronchodilator and underwent hospitalized in January 2015-December 2015 (n=108). Patient data were collected from the medical record. Data were analyzed using univariate and bivariate to count the number of occurrences of hypertension and recognizing the correlation between the duration of the use of β2 agonists with hypertension event.Results: The incidence of hypertension in patients with asthma who were treated with beta-2 agonists are 50, 93% at the stage of pre-hypertension (120 mm Hg/80 mm Hg) and 25, 9% in stage I hypertension (140 mmHg/90 mmHg). Body weight and duration of therapy with a β2 agonist positively correlated with the incidence of hypertension with a correlation coefficient (r) 0.231 and 0.386 respectively. Conclusion:In this study, duration of therapy with a β2 agonist in asthma patients positively correlated with the incidence of hypertension.

Leptin and Adiponectin Levels of Asthmatic Iraqi Children in Hilla Province

“…Body weight is one of the risk factors in asthma. Obesity is marked by low levels of systemic inflammation with elevated levels of inflammatory cytokines, adipokines, and acute phase proteins, including leptin, IL-6, TNF-α, and C-reactive protein [17][18][19]. Indeed, obesity facilitates the development of metabolic disorders and cardiovascular diseases in addition to chronic diseases [20][21][22].…”